Actinogen Medical Limited

Actinogen Medical Limited, a biotechnology company, develops therapies for neurological and neuropsychiatric diseases associated with dysregulated brain cortisol in Australia. It is developing Xanamem, an inhibitor of the 11ß-HSD1 enzyme, which is in Phase 2 clinical trials that achieves target engagement in the central nervous system, Alzheimer's disease, depression with cognitive impairment, and anxiety, sleep, and behavioral problems in fragile X syndrome. Show More...

  • Website https://www.actinogen.com.au
  • Sector Healthcare
  • Industry Biotechnology
  • Last Quote 0.01 EUR
  • Last Updated 29-05-2025
  • External Links Yahoo Finance Morningstar Ratios
  •   2010-06 2011-06 2012-06 2013-06 2014-06 2015-06 2016-06 2017-06 2018-06 2019-06 TTM
    Earnings Per Share AUD -0.03 -0.03 -0.04 -0.010 -0.010 -0.010 -0.010 -0.010
    Dividends AUD
    Payout Ratio % *
    Shares Mil 23.0 22.0 36.0 45.0 153.0 412.0 606.0 609.0 705.0 1.102 1.118
    Book Value Per Share * EUR 0.04 0.03 0.010 0.010 0.010 0.010 0.02 0.010 0.010 0.010 0.010
    Free Cash Flow Per Share * EUR -0.02 -0.03 -0.03 -0.010 -0.010
    Return on Assets % -44.03 -59.81 -190.36 -44.42 -57.27 -64.5 -25.47 -27.55 -44.13 -57.74 -40.66
    Financial Leverage (Average) 1.15 1.09 1.34 1.42 1.04 1.01 1.07 1.09 1.04 1.04 1.04
    Return on Equity % -48.04 -67.05 -219.53 -60.84 -62.61 -65.56 -26.44 -29.69 -46.81 -60.07 -44.88
    Return on Invested Capital % -50.32 -69.31 -220.99 -61.33 -64.54 -65.5 -27.16 -29.96 -47.01 -61.26 -44.81
    Interest Coverage -951.62 -635.27 -608.73 -563.69 -372.93 -542.83 -343.48
    Current Ratio 6.44 9.58 2.4 1.69 23.11 45.01 9.4 6.35 17.62 22.47 22.47
    Quick Ratio 6.44 9.42 1.91 1.44 22.8 44.86 9.35 6.31 17.56 22.37 22.37
    Debt/Equity